4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperazin-2-yl)propoxy]quinoline-3-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperazin-2-yl)propoxy]quinoline-3-carbonitrile
• 英文别名: 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperazin-2-yl)propoxy]quinoline-3-carbonitrile
• 化学式: C₂₆H₂₉Cl₂N₅O₃
• 分子量: 530.4
• InChiKey: IALPCIQQCWSFDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• COMBINATION THERAPIES
  申请人：Mirati Therapeutics, Inc.

  公开号：EP3849534A1

  公开（公告）日：2021-07-21
• [EN] COMBINATION THERAPIES<br/>[FR] POLYTHÉRAPIES
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2020055755A1

  公开（公告）日：2020-03-19

  The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Src-family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.